NAVERIS
Naveris is a biotechnology company that provides highly sensitive blood tests for cancers to enable early diagnosis in the general asymptomatic population, real-time monitoring of response in patients undergoing treatment, and detection of cancer recurrence in patients in remission. The company's 3D biomimetic technology replicates the morphological, signaling, and cell lineage complexity of human tissues and tumors ex vivo. By empowering investigators to efficiently establish patient tumors ex vivo, its technology enables innovative designs for oncology clinical trials and precision medicine that seek to match the right therapies with the right patients. Naveris was founded in 2017 and is headquartered in Waltham, Massachusetts.
NAVERIS
Industry:
Biotechnology Health Care Medical
Founded:
2017-01-01
Address:
Waltham, Massachusetts, United States
Country:
United States
Website Url:
http://www.naveris.com
Total Employee:
1+
Status:
Active
Contact:
(833)-628-3747
Email Addresses:
[email protected]
Total Funding:
15.44 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Font Awesome Global Site Tag
Similar Organizations
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
ORIG3N
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases.
Watchmaker Genomics
Watchmaker Genomics is a biotechnology company that focuses on breakthrough applications for reading, writing, and editing DNA.
Current Advisors List
Current Employees Featured
Founder
Investors List
R-Cubed Capital Partners
R-Cubed Capital Partners investment in Series A - Naveris
Gurnet Point Capital
Gurnet Point Capital investment in Series A - Naveris
Sky Ventures Group
Sky Ventures Group investment in Series A - Naveris
TechU Ventures
TechU Ventures investment in Seed Round - Naveris
Sky Ventures Group
Sky Ventures Group investment in Seed Round - Naveris
Official Site Inspections
http://www.naveris.com Semrush global rank: 5.62 M Semrush visits lastest month: 1.51 K
- Host name: 58.68.167.72.host.secureserver.net
- IP address: 72.167.68.58
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Naveris"
Naveris | Transformative Technologies for Early Cancer Detection
Our mission at Naveris is to deliver disruptive technology with the potential to transform cancer detection and improve patient outcomes. Naveris develops highly sensitive blood tests that …See details»
Naveris - Crunchbase Company Profile & Funding
Naveris is a biotechnology company that provides clinically validated blood tests for the early detection of cancer. View contacts for Naveris to access new leads and connect with decision …See details»
Leadership - Naveris
James McNally is the Chief Executive Officer for Naveris. Previously, he was President and CEO of Digma Medical, a clinical stage medical device company developing novel therapeutics for metabolic disease.See details»
About - Naveris
Naveris has developed highly sensitive blood tests for cancers to enable early diagnosis in the general asymptomatic population, real-time monitoring of response in patients undergoing treatment, and detection of cancer …See details»
Naveris Company Profile 2024: Valuation, Funding & Investors
Naveris was founded in 2017. Where is Naveris headquartered? Naveris is headquartered in Natick, MA. What is the size of Naveris? Naveris has 53 total employees. What industry is …See details»
NAVERIS - LinkedIn
Transformative Technologies for Early Cancer Detection. Naveris® Inc. is a molecular diagnostics company developing and commercializing novel blood and saliva tests to enhance the early …See details»
Naveris | North Carolina Biotech Center
Naveris has developed highly sensitive blood tests for cancers to enable early diagnosis in the general asymptomatic population, real-time monitoring of response in patients undergoing …See details»
Naveris - VentureRadar
Website: https://naveris.com/ Develops novel molecular diagnostics for early detection of viral cancers using proprietary DNA fragmentomics technology in blood tests. VentureRadar …See details»
NAVERIS's Board of Directors - Team members and org chart
NAVERIS's Board of Directors includes Gaorav Gupta and 2 others.See details»
The NAVigate-HPV Registry: A comprehensive biomarker evidence …
May 29, 2024 · Methods: NavDx (Naveris, Inc.) is a clinically validated blood-based assay detecting circulating cell-free tumor tissue modified viral (TTMV)-HPV DNA. The NAVigate …See details»
Naveris, Inc. Raises $19 Million in Financing to Advance and ...
Dec 15, 2020 · Naveris, Inc. is a molecular diagnostics company developing and bringing to market novel blood tests to enhance the early detection and clinical management of viral …See details»
Dr. Stephen Naber - Laboratory Director at NAVERIS | The Org
Dr. Stephen Naber began their career in 2002 as a Senior Pathologist at Tufts Medical Center. Stephen then went on to become the Medical Director of the Biorepository, Chief of Anatomic …See details»
Naveris, Inc. Raises $51 Million to Advance ... - Business Wire
Sep 19, 2022 · Naveris’ blood tests for earlier cancer detection use proprietary patented DNA fragmentomics technology to distinguish between viral DNA arising from cancers versus infection.See details»
Analytical Validation of NavDx, a cfDNA-Based Fragmentomic …
Here, we report a detailed analytical validation of the NavDx assay, including sample stability, specificity as measured by limits of blank (LOBs), and sensitivity illustrated via limits of …See details»
Naveris Unveils NAVigate-HPV: A Groundbreaking Registry to …
WALTHAM, Mass. (March 1, 2024) – Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the launch of the NAVigate-HPV Registry.See details»
Naveris Unveils NAVigate-HPV: A Groundbreaking Registry to …
Mar 1, 2024 · Building on this strong and growing clinical evidence base, the NAVigate-HPV Registry will enrich understanding of HPV-driven cancers while fostering a collaborative …See details»
Naveris' New Saliva Test Detects Head and Neck Cancer
Jun 2, 2021 · Naveris, Inc. is a molecular diagnostics company developing and commercializing novel blood and saliva tests to enhance the early detection and clinical management of viral …See details»
Naveris, Inc. Raises $51 Million to Advance Commercialization of …
Natick, MA., September 19, 2022 –(BUSINESS WIRE)– Naveris, Inc., a commercial-stage life sciences company dedicated to improving patient care through earlier detection of viral-driven …See details»
New Saliva Test Detects Head and Neck Cancer - American Society …
Researchers at Washington University School of Medicine in St. Louis used the Naveris, Inc. test to analyze saliva for sequences of the human papilloma virus (HPV) genome that are specific …See details»
Clinical Operations Analyst - Naveris
Aug 29, 2024 · Naveris is seeking a Clinical Operations Analyst to join our Business Operations team. The Clinical Operations Analyst will support ordering providers and help patients at risk …See details»